– STELLAR-305 is Exelixis’ first pivotal study in squamous cell carcinoma of the head and neck –
– Trial will evaluate the potential of inhibition of VEGF, MET and AXL, which are elevated.
Exelixis (EXEL) Announces More Detailed Results of Phase 3 COSMIC-313 Trial in Advanced Kidney Cancer at ESMO streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
– Cabozantinib in combination with nivolumab and ipilimumab significantly reduced the risk of disease progression or death compared with the combination of nivolumab and ipilimumab –– Median progression-free survival was not yet reached with the combination of cabozantinib, nivolumab and ipilimumab versus 11.3 month.
08.09.2022 - Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from COSMIC-313, an ongoing phase 3 pivotal trial evaluating the combination of cabozantinib (CABOMETYX), nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in .